• Aeterna Zentaris Inc., of Quebec City, said Phase I results of its oral cancer compound, perifosine, in multiple myeloma, were published in the online issue of the British Journal of Haematology. The article reviews the safety profile and clinical activity of the PI3K/Akt pathway inhibitor when combined with Revlimid (lenalidomide, Celgene Corp.) and dexamethasone in relapsed and relapsed/refractory multiple myeloma. Perifosine is partnered with Keryx Biopharmaceuticals Inc., of New York.
Suite: 1100 | Atlanta, Georgia 30346, USA
In the U.S. and Canada: 1-855-260-5607
Outside the U.S.: 1-646-822-4549
In the U.S. and Canada: 1-800-336-4474
Outside the U.S.: 1-215-386-0100
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter